AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Learn more →

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

A survey study based on international consensus building for the development and further improvement of medical guidelines for Castleman's disease, TAFRO syndrome and related diseases; RADDAR-J[77]

Not Applicable

Recruiting

Conditions: Castleman&#39
s disease, TAFRO syndrome and related diseases

Registration Number: JPRN-UMIN000046356

Lead Sponsor: Ministry of Health, Labour and Welfare

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 1000

Inclusion Criteria

Not provided

Exclusion Criteria

Patients judged to be inappropriate as a target by the judgment of researchers.

Study & Design

Study Type: Observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method

Secondary Outcome Measures

Name	Time	Method

Related Trials

Study in several countries to assess the proportion of adult women (25-45 yrs) who accept to receive the HPV vaccine, the reasons to accept it and how many of these women receive the three doses and why.

Phase 1

Ghent University Hospital

Updated 11/25/2019

Study in several countries to assess the proportion of adult women (25-45 yrs) who accept to receive the HPV vaccine, the reasons to accept it and how many of these women receive the three doses and why.

Phase 1

Catalan Institute of Oncology

Updated 4/30/2019

Study in several countries to assess the proportion of adult women (25-45 yrs) who accept to receive the HPV vaccine, the reasons to accept it and how many of these women receive the three doses and why.

Phase 1

Catalan Institute of Oncology

Updated 4/5/2021

Study in several countries to assess the proportion of adult women (25-45 yrs) who accept to receive the HPV vaccine, the reasons to accept it and how many of these women receive the three doses and why.

Phase 1

Catalan Institute of Oncology

Updated 8/20/2018

Study in several countries to assess the proportion of adult women (25-45 yrs) who accept to receive the HPV vaccine, the reasons to accept it and how many of these women receive the three doses and why.

Phase 1

Catalan Institute of Oncology

Updated 4/19/2022

International survey to investigate the implementation of daily ICU care for patients with and without COVID-19 infection. A Point Prevalence Study -ISIIC 2 Study

Not Applicable

Saiseikai Utsunomiya Hospital Hitachi General Hospital

Updated 10/17/2023

A study to determine patient specific and general beliefs towards medication and their treatment compliance to selected systemic therapies in chronic inflammatory diseases (ALIGN)

RecruitingNot Applicable

AbbVie Pty Ltd

Updated 1/13/2020

Multinational study assessing the acceptability and determinants of compliance to HPV vaccination to women in screening ages 25 to 45 years

WithdrawnPhase 4

Vrije Universiteit Medisch Centrum

Updated 4/23/2024

Study in several countries to asess the proportion of adult women (30-45 years) WHO accept to receive the HPV vaccine, the reasons to accept it and how many of these women who receive three doses of the vaccine.

Phase 1

Catalan Institute of Oncology

Updated 12/16/2019

Study in several countries to asess the proportion of adult women (25-45 years) WHO accept to receive the HPV vaccine, the reasons to accept it and how many of these women who receive three doses of the vaccine.

Phase 1

Catalan Institute of Oncology

Updated 11/25/2019

Home Terms & Conditions Privacy Policy

AI-Powered Research

Premium Access

A survey study based on international consensus building for the development and further improvement of medical guidelines for Castleman&#39;s disease, TAFRO syndrome and related diseases; RADDAR-J[77]

Recruitment & Eligibility

Study & Design

Related Trials

Study in several countries to assess the proportion of adult women (25-45 yrs) who accept to receive the HPV vaccine, the reasons to accept it and how many of these women receive the three doses and why.

Study in several countries to assess the proportion of adult women (25-45 yrs) who accept to receive the HPV vaccine, the reasons to accept it and how many of these women receive the three doses and why.

Study in several countries to assess the proportion of adult women (25-45 yrs) who accept to receive the HPV vaccine, the reasons to accept it and how many of these women receive the three doses and why.

Study in several countries to assess the proportion of adult women (25-45 yrs) who accept to receive the HPV vaccine, the reasons to accept it and how many of these women receive the three doses and why.

Study in several countries to assess the proportion of adult women (25-45 yrs) who accept to receive the HPV vaccine, the reasons to accept it and how many of these women receive the three doses and why.

International survey to investigate the implementation of daily ICU care for patients with and without COVID-19 infection. A Point Prevalence Study -ISIIC 2 Study

A study to determine patient specific and general beliefs towards medication and their treatment compliance to selected systemic therapies in chronic inflammatory diseases (ALIGN)

Multinational study assessing the acceptability and determinants of compliance to HPV vaccination to women in screening ages 25 to 45 years

Study in several countries to asess the proportion of adult women (30-45 years) WHO accept to receive the HPV vaccine, the reasons to accept it and how many of these women who receive three doses of the vaccine.

Study in several countries to asess the proportion of adult women (25-45 years) WHO accept to receive the HPV vaccine, the reasons to accept it and how many of these women who receive three doses of the vaccine.

A survey study based on international consensus building for the development and further improvement of medical guidelines for Castleman's disease, TAFRO syndrome and related diseases; RADDAR-J[77]